Oncology & Cancer

Three-drug combination slows progression of advanced kidney cancer

A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer in previously untreated patients, according to research led by an oncologist from Dana-Farber Cancer ...

Medications

Update shows relatlimab + nivolumab slows advanced melanoma

For patients with previously untreated metastatic or unresectable melanoma, the combination of relatlimab + nivolumab continues to demonstrate a progression-free survival (PFS) benefit over nivolumab alone, according to updated ...

Oncology & Cancer

Treatments compared for advanced renal cell carcinoma

(HealthDay)—For patients with advanced renal cell carcinoma (aRCC), those initiating treatment with nivolumab plus ipilimumab versus sunitinib have longer treatment-free survival (TFS), according to a study published online ...

page 1 from 5